Prana looks at Huntington’s
Tuesday, 02 December, 2008
Melbourne company Prana Biotechnology is investigating the potential of its lead compound, PBT2, in Huntington’s disease.
PBT2, a metal-protein-attenuating compound (MPAC), is in Phase IIb clinical trials for Alzheimer’s disease.
The compound reduces the toxic metal-protein interaction seen in both neurological diseases and has a neuroprotective effect.
Chairman of Prana’s R&D advisory board, Professor Jeffery Cummings, told the company’s AGM that a report commissioned from an independent clinical research group recommended that Prana proceed to clinical trials.
Prana is in confidential talks with several pharma companies with a view to licensing PBT2, the company said.
Scientists search for cystitis pain 'off switch'
By targeting certain pain receptors in the bladder, Australian scientists believe that the...
Australia's first cases of H5 avian influenza confirmed
Positive results for H5 avian influenza (bird flu) have been confirmed in two seabirds found in...
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
